Predicting MCI Outcome With Clinically Available MRI And CSF Biomarkers

November 18, 2023
< 1 mins

Category: Published research

Study to determine the ability of clinically available volumetric MRI (vMRI) and CSF biomarkers, alone or in combination with a quantitative learning measure, to predict conversion to Alzheimer’s disease (AD) in patients with mild cognitive impairment (MCI). 2011 October 12.

[button]Download[/button]

Topic: Published research

More Resources

11/17/2025

Unlocking the Value of NeuroQuant Reports: Different Use Cases Across Clinical Practice

From neurodegeneration and demyelination to development, trauma, and seizures, NeuroQuant supports better decision‑making, communication, and patient care

Blogs

11/17/2025

Case Study: Augmenting Prostate Imaging Programs with OnQ™ Prostate

Discover how Imaging Healthcare Specialists integrated OnQ™ Prostate to enhance lesion visibility, boost diagnostic confidence, and improve communication.

Case studies

11/04/2025

NeuroQuant Dementia in Different Use Cases

NeuroQuant transforms brain imaging into a measurable biomarker for neurodegeneration by combining volumetric data with clinical expertise.

Blogs

10/29/2025

Enhancing Brain Tumor Treatment with RT STRUCT Images: The Promise of Automation

Automating the generation of RT STRUCT images with NeuroQuant Brain Tumor can streamline workflows and elevate the standard of care

Blogs, Product updates

10/15/2025

Sharper Screening, Smarter Biopsies: OnQ Prostate and the Next Step in Imaging

Read to learn how OnQ Prostate goes beyond existing solutions like DynaCAD and redefines biopsy precision

Blogs

10/14/2025

Cortechs.ai Acquires ZepMed to Expand AI-Powered Neuroimaging Capabilities

This strategic acquisition strengthens Cortechs.ai’s position at the forefront of radiological innovation and expands its suite of best-in-class solutions

Our solutions

Our solutions

About

Support

Resources